1. Home
  2. JCE vs ALT Comparison

JCE vs ALT Comparison

Compare JCE & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JCE
  • ALT
  • Stock Information
  • Founded
  • JCE 2007
  • ALT 1997
  • Country
  • JCE United States
  • ALT United States
  • Employees
  • JCE N/A
  • ALT N/A
  • Industry
  • JCE Trusts Except Educational Religious and Charitable
  • ALT Biotechnology: Pharmaceutical Preparations
  • Sector
  • JCE Finance
  • ALT Health Care
  • Exchange
  • JCE Nasdaq
  • ALT Nasdaq
  • Market Cap
  • JCE 256.5M
  • ALT 292.0M
  • IPO Year
  • JCE N/A
  • ALT N/A
  • Fundamental
  • Price
  • JCE $15.63
  • ALT $3.63
  • Analyst Decision
  • JCE
  • ALT Strong Buy
  • Analyst Count
  • JCE 0
  • ALT 6
  • Target Price
  • JCE N/A
  • ALT $17.40
  • AVG Volume (30 Days)
  • JCE 49.7K
  • ALT 3.0M
  • Earning Date
  • JCE 01-01-0001
  • ALT 08-12-2025
  • Dividend Yield
  • JCE 9.26%
  • ALT N/A
  • EPS Growth
  • JCE N/A
  • ALT N/A
  • EPS
  • JCE N/A
  • ALT N/A
  • Revenue
  • JCE N/A
  • ALT $20,000.00
  • Revenue This Year
  • JCE N/A
  • ALT N/A
  • Revenue Next Year
  • JCE N/A
  • ALT $346,228.97
  • P/E Ratio
  • JCE N/A
  • ALT N/A
  • Revenue Growth
  • JCE N/A
  • ALT N/A
  • 52 Week Low
  • JCE $11.64
  • ALT $2.90
  • 52 Week High
  • JCE $14.28
  • ALT $11.16
  • Technical
  • Relative Strength Index (RSI)
  • JCE 59.52
  • ALT 40.61
  • Support Level
  • JCE $15.59
  • ALT $3.34
  • Resistance Level
  • JCE $15.85
  • ALT $3.91
  • Average True Range (ATR)
  • JCE 0.18
  • ALT 0.20
  • MACD
  • JCE 0.02
  • ALT 0.06
  • Stochastic Oscillator
  • JCE 70.27
  • ALT 42.69

About JCE Nuveen Core Equity Alpha Fund of Beneficial Interest

Nuveen Core Equity Alpha Fund is a diversified closed-end management investment company. Its investment objective is to provide an attractive level of total return, through long-term capital appreciation and through income and gains. The Fund invests in a portfolio of actively managed large-capitalization U.S. common stocks, using the sub-adviser's proprietary quantitative process designed to provide the potential for long-term outperformance. Additionally, the Fund seeks to reduce the volatility of its returns relative to the returns of the Equity Portfolio over extended periods by writing (selling) index call options and/or call options on custom baskets of securities.

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: